Silvitra 120 Tablet

Q1: What is Silvitra 120?

Silvitra 120 is a unique dual PDE-5 inhibitor combination tablet by RSM Multilink LLP containing Sildenafil 100mg and Vardenafil 20mg. Unlike the Sildalist products that combine sildenafil and tadalafil, Silvitra combines two fast-acting PDE-5 inhibitors from different chemical classes for complementary dual-class ED coverage.

Q2: How does combining sildenafil and vardenafil differ from other combinations?

Both sildenafil and vardenafil are fast-acting PDE-5 inhibitors (4–6 hour window) but belong to different chemical classes. Vardenafil has approximately 10× higher PDE-5 selectivity than sildenafil and may produce faster onset. Their combination provides dual-class PDE-5 blockade, potentially more effective for men not responding adequately to either alone.

Q3: How quickly does Silvitra 120 work?

The vardenafil component has a reported faster onset (15–30 minutes) than sildenafil, while sildenafil's onset is 30–60 minutes. Together, the combination may produce faster initial erection response than sildenafil alone, though empty-stomach administration is important for optimal sildenafil bioavailability.

Q4: How long does Silvitra 120 last?

Both sildenafil and vardenafil have 4–6 hour activity windows. Silvitra 120 provides the same 4–6 hour therapeutic duration as either component, but with combined pharmacological strength throughout the entire window.

Q5: Is Silvitra 120 safer than the Sildalist products?

Both Silvitra 120 and the Sildalist products are dual-combination PDE-5 inhibitors requiring physician supervision. Silvitra 120 combines two fast-acting agents rather than a fast-acting and extended-duration agent. The cardiovascular risk from combined PDE-5 inhibition applies to all dual-combination products.

Q6: What is the QT prolongation concern with Silvitra 120?

Vardenafil has a known mild QT-prolonging effect. This is relevant in Silvitra 120 because the combination with sildenafil adds further vascular effects. Men with QT prolongation, those taking QT-prolonging medications, or those with known cardiac arrhythmias must not use this product.

Q7: What side effects does Silvitra 120 cause?

Combined adverse effects include headache, facial flushing, nasal congestion, visual colour tinge (from sildenafil), indigestion, and dizziness — with vardenafil adding its own similar profile. The compounded effects are more pronounced than either drug alone.

Q8: Who should not take Silvitra 120?

Men taking organic nitrates, riociguat, alpha-blockers, QT-prolonging drugs, antiarrhythmics, or those with cardiovascular disease, recent MI or stroke, QT prolongation, severe hepatic impairment, uncontrolled hypertension, retinal disease, or hearing disorders are contraindicated.

Q9: Can Silvitra 120 cause priapism?

Yes. The combined PDE-5 inhibition from two concurrent agents increases priapism risk above either drug used alone. Any erection lasting more than 4 hours is a medical emergency requiring immediate treatment.

Q10: Can alcohol be taken with Silvitra 120?

Alcohol should be avoided or strictly minimised with Silvitra 120. The dual-agent hypotensive effect combined with alcohol creates substantial cardiovascular risk not present with single-agent therapy.

Q11: Is Silvitra 120 appropriate for first-time ED treatment?

No. Silvitra 120 is a dual-combination product for men who require enhanced therapy beyond single-agent PDE-5 inhibitors under physician supervision. Starting ED therapy with a dual-combination product is not appropriate for first-line treatment.

Q12: Is a prescription required for Silvitra 120?

Yes, and physician cardiovascular assessment is specifically required before use. The dual-class PDE-5 inhibition of Silvitra 120 amplifies vascular effects and requires medical evaluation to confirm safety for this combined therapy.